EcoDrugPlus

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSMMNG00015013288
Gene Symbol: PSMB9
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSMMNG00015004070
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSMMNG00015015484
Gene Symbol: PSMC1
3 Cross references
175 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSMMNG00015007104
Gene Symbol: PSMC2
3 Cross references
227 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSMMNG00015021802
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSMMNG00015001827
Gene Symbol: PSMC4
3 Cross references
197 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSMMNG00015020703
Gene Symbol: PSMC5
3 Cross references
225 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSMMNG00015016393
Gene Symbol: PSMC6
3 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSMMNG00015011392
Gene Symbol: PSMD1
3 Cross references
210 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSMMNG00015021150
Gene Symbol: PSMD11
1 Cross references
285 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSMMNG00015017282
Gene Symbol: PSMD12
3 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSMMNG00015021798
Gene Symbol: PSMD13
3 Cross references
220 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).